Download PDF
Semin Thromb Hemost 2021; 47(06): 709-723
DOI: 10.1055/s-0041-1725057
Review Article

Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis

Jesus Aibar
1   Department of Internal Medicine, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
2   Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
,
Sam Schulman
2   Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
3   Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
› Author Affiliations Funding This work was supported by a grant from Hospital Clinic, IDIBAPS and University of Barcelona (Estada Retribuïda per ampliació d'estudis).
› Further Information
    Permissions and Reprints

Corrected by:

Erratum: Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-AnalysisSemin Thromb Hemost 2021; 47(06): e1-e2
DOI: 10.1055/s-0042-1757330

Abstract

There is a scarcity of high-quality randomized controlled trials (RCTs) comparing antithrombotic regimens for secondary prevention of arterial thrombosis (AT) in antiphospholipid syndrome (APS). We reviewed different antithrombotic regimens used for this purpose. We searched for studies on management of AT in APS on PubMed and Web of Science. Eleven studies (5 RCTs, 3 prospective, and 3 retrospective cohort studies) comparing different regimens and reporting outcomes specifically for patients with index AT events were identified. Treatments were vitamin K antagonists (VKA; 9 studies), non-VKA oral anticoagulant (NOAC; 3 studies), single antiplatelet therapy (SAPT; 7 studies), dual antiplatelet therapy (DAPT; 2 studies), and VKA combined with SAPT (4 studies). We performed a meta-analysis for the outcomes: recurrent AT, any (arterial or venous) recurrent thromboembolism, and major bleeding. Recurrent AT was reduced with VKA plus SAPT versus VKA (risk ratio [RR]: 0.43; 95% confidence interval [CI]: 0.22–0.85) and with DAPT versus SAPT (RR: 0.29; 95% CI: 0.09–0.99). Any recurrent thromboembolism was reduced with VKA plus SAPT versus VKA alone (RR: 0.41; 95% CI: 0.24–0.69) and versus SAPT alone (RR: 0.36; 95% CI: 0.13–0.96). There were no significant differences between other treatments for thromboembolism and for none of the comparisons regarding major bleeding. In a sensitivity analysis, excluding low-quality studies, VKA was more effective than NOAC to prevent recurrent AT (RR: 0.25; 95% CI: 0.07–0.93). Combined antithrombotic therapy might be more effective than single agents as secondary prophylaxis in APS with AT, and does not seem to compromise with safety, but the quality of evidence is generally low. NOACs should be avoided for patients with APS and AT.

Keywords

antiphospholipid syndrome - arterial thrombosis - stroke - recurrence - bleeding


Publication History

Article published online:
10 May 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
    Google Scholar
  • 2 Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42 (07) 1309-1311
    Google Scholar
  • 3 Duarte-García A, Pham MM, Crowson CS. et al. The epidemiology of antiphospholipid syndrome: a population-based study. Arthritis Rheumatol 2019; 71 (09) 1545-1552
    Google Scholar
  • 4 Hwang JJ, Shin SH, Kim YJ. et al. Epidemiology of antiphospholipid syndrome in Korea: a nationwide population-based study. J Korean Med Sci 2020; 35 (05) e35
    Google Scholar
  • 5 Kearon C, Parpia S, Spencer FA. et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood 2018; 131 (19) 2151-2160
    Google Scholar
  • 6 Tektonidou MG, Andreoli L, Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78 (10) 1296-1304
    Google Scholar
  • 7 Tektonidou MG, Ioannidis JPA, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM 2000; 93 (08) 523-530
    Google Scholar
  • 8 Dufrost V, Risse J, Reshetnyak T. et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev 2018; 17 (10) 1011-1021
    Google Scholar
  • 9 Oku K, Amengual O, Yasuda S, Atsumi T. How to identify high-risk APS patients: clinical utility and predictive values of validated scores. Curr Rheumatol Rep 2017; 19 (08) 51
    Google Scholar
  • 10 Fujieda Y, Atsumi T, Amengual O. et al. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus 2012; 21 (14) 1506-1514
    Google Scholar
  • 11 Taraborelli M, Reggia R, Dall'Ara F. et al. Longterm outcome of patients with primary antiphospholipid syndrome: a retrospective multicenter study. J Rheumatol 2017; 44 (08) 1165-1172
    Google Scholar
  • 12 Pengo V, Ruffatti A, Legnani C. et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8 (02) 237-242
    Google Scholar
  • 13 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (05) 1827-1832
    Google Scholar
  • 14 Schulman S, Svenungsson E, Granqvist S. Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104 (04) 332-338
    Google Scholar
  • 15 Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I. et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20 (02) 206-218
    Google Scholar
  • 16 Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157 (01) 47-58
    Google Scholar
  • 17 Limper M, de Leeuw K, Lely AT. et al. Diagnosing and treating antiphospholipid syndrome: a consensus paper. Neth J Med 2019; 77 (03) 98-108
    Google Scholar
  • 18 Jackson WG, Oromendia C, Unlu O, Erkan D, DeSancho MT. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv 2017; 1 (25) 2320-2324
    Google Scholar
  • 19 Levine SR, Brey RL, Tilley BC. et al; APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291 (05) 576-584
    Google Scholar
  • 20 Yamazaki M, Kadohira Y, Maekawa M. et al. Combined antiplatelet agents might help prevent arterial thrombosis in antiphospholipid syndrome. J Thromb Haemost 2009; 7 (Suppl. 02) 720-721
    Google Scholar
  • 21 Malec K, Broniatowska E, Undas A. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. Lupus 2020; 29 (01) 37-44
    Google Scholar
  • 22 Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17 (01) 1-12
    Google Scholar
  • 23 Wells G, Shea B, O'Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013 . Accessed October 9, 2020 at: http://wwwohrica/programs/clinical_epidemiology/oxfordasp
    Google Scholar
  • 24 Crowther MA, Ginsberg JS, Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349 (12) 1133-1138
    Google Scholar
  • 25 Okuma H, Kitagawa Y, Yasuda T, Tokuoka K, Takagi S. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci 2009; 7 (01) 15-18
    Google Scholar
  • 26 Arauz A, Roa LF, Hernandez B. et al. Aspirin versus anticoagulation in young patients with cerebral infarction secondary to primary antiphospholipid syndrome [in Spanish]. Rev Neurol 2011; 53 (10) 584-590
    Google Scholar
  • 27 Pyo JY, Jung SM, Lee SW, Song JJ, Lee SK, Park YB. Subsequent thrombotic outcomes in patients with ischemic stroke with antiphospholipid antibody positivity. Yonsei Med J 2017; 58 (06) 1128-1134
    Google Scholar
  • 28 Ohnishi N, Fujieda Y, Hisada R. et al. Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. Rheumatology (Oxford) 2019; 58 (06) 969-974
    Google Scholar
  • 29 Pengo V, Denas G, Zoppellaro G. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132 (13) 1365-1371
    Google Scholar
  • 30 Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M. et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019; 171 (10) 685-694
    Google Scholar
  • 31 Pengo V, Banzato A, Bison E, Zoppellaro G, Padayattil Jose S, Denas G. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 2016; 25 (03) 301-306
    Google Scholar
  • 32 Cervera R, Piette JC, Font J. et al; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46 (04) 1019-1027
    Google Scholar
  • 33 Cervera R, Boffa MC, Khamashta MA, Hughes GRV. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009; 18 (10) 889-893
    Google Scholar
  • 34 Ricarte IF, Dutra LA, Abrantes FF. et al. Neurologic manifestations of antiphospholipid syndrome. Lupus 2018; 27 (09) 1404-1414
    Google Scholar
  • 35 Uthman I, Noureldine MHA, Ruiz-Irastorza G, Khamashta M. Management of antiphospholipid syndrome. Ann Rheum Dis 2019; 78 (02) 155-161
    Google Scholar
  • 36 Soltész P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients. Lupus 2003; 12 (04) 302-307
    Google Scholar
  • 37 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    Google Scholar
  • 38 Cuadrado MJ, Bertolaccini ML, Seed PT. et al. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford) 2014; 53 (02) 275-284
    Google Scholar
  • 39 Verro P, Levine SR, Tietjen GE. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke 1998; 29 (11) 2245-2253
    Google Scholar
  • 40 Wang CR, Liu MF. Rituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: a single-center experience. Semin Arthritis Rheum 2016; 46 (01) 102-108
    Google Scholar
  • 41 Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GRV. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002; 162 (10) 1164-1169
    Google Scholar
  • 42 Derksen RH, de Groot PG, Kappelle LJ. Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. Neurology 2003; 61 (01) 111-114
    Google Scholar
  • 43 Finazzi G, Marchioli R, Brancaccio V. et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3 (05) 848-853
    Google Scholar
  • 44 Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332 (15) 993-997
    Google Scholar
  • 45 Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117 (04) 303-308
    Google Scholar
  • 46 Lopes LC, Spencer FA, Neumann I. et al. Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis. Clin Pharmacol Ther 2013; 94 (03) 367-375
    Google Scholar
  • 47 Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124 (15) 2450-2458
    Google Scholar